Get the Stockscreener App
46.39
3.35%
-1.61
After Hours:
44.08
-2.31
-4.98%
Janux Therapeutics Inc stock is traded at $46.39, with a volume of 646.31K.
It is down -3.35% in the last 24 hours and down -13.14% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$48.00
Open:
$48.1
24h Volume:
646.31K
Relative Volume:
1.04
Market Cap:
$2.50B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-28.46
EPS:
-1.63
Net Cash Flow:
$-37.82M
1W Performance:
-5.25%
1M Performance:
-13.14%
6M Performance:
+2.25%
1Y Performance:
+362.05%
1-Day Range:
$46.30
$49.69
1-Week Range:
$45.95
$52.38
52-Week Range:
$7.79
$65.60
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
46.39 | 2.50B | 13.05M | -60.54M | -37.82M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics CEO David Campbell sells $1.3 million in stock - Investing.com
How Are Things Looking For Janux Therapeutics Inc (NASDAQ: JANX) For The Short Term? - Stocks Register
Victory Capital Management Inc. Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Janux to Present JANX007 Phase 1a Clinical Data for Prostate Cancer Treatment | JANX Stock News - StockTitan
Janux Therapeutics initiated with an Outperform at Leerink - MSN
Leerink Partnrs Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-Buy - Defense World
Leerink Partners Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Objective long/short (JANX) Report - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of Janux Therapeutics (JANX) with Outperform Recommendation - MSN
Leerink sets shares target on Janux Therapeutics, cites platform By Investing.com - Investing.com Canada
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts - Benzinga
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at Leerink Partners - MarketBeat
Janux Therapeutics’ Q3 Report: Financials and Progress - TipRanks
Stifel Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha
Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors - MSN
Citadel Advisors LLC Adjusts Stake in Janux Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (JANX) - Stock Traders Daily
FMR LLC's Strategic Acquisition of Janux Therapeutics Shares - GuruFocus.com
William Blair Predicts Lower Earnings for Janux Therapeutics - Defense World
HC Wainwright Has Negative Outlook of JANX FY2024 Earnings - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright's Forecast for JANX FY2024 Earnings? - MarketBeat
William Blair Issues Pessimistic Forecast for JANX Earnings - MarketBeat
Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Janux Therapeutics earnings missed by $0.18, revenue fell short of estimates - Investing.com UK
Janux Therapeutics price target raised to $82 from $62 at BTIG - TipRanks
Janux Therapeutics Cash Soars to $658M Despite Widening Q3 Losses; Trial Updates Ahead | JANX Stock News - StockTitan
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Nisa Investment Advisors LLC Has $924,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.3%Here's Why - MarketBeat
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia
Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St
Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
Janux therapeutics sees significant stock sale by major shareholder Jay Lichter for $178,084 - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials - openPR
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics - Barchart
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):